

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Yair REISNER et al

Serial No.: 10/759,033

Filed: January 20, 2004

For: METHODS OF TREATING DISEASE BY
TRANSPLANTATION OF DEVELOPING ALLO-
GENEIC OR XENOGENEIC ORGANS OR TISSUES

Examiner: LANKFORD JR, LEON B

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

[illegible]

Group Art Unit: 1651

Attorney
Docket: 27132

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.


This Supplemental Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Martin D. Moynihan

Martin D. Moynihan
Registration No. 40,338

Dated: September 10, 2006



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/759,033
				Filing Date	January 20, 2004
				First Named Inventor	Yair REISNER et al
				Group Art Unit	1651
				Examiner Name	LANKFORD JR, LEON B
Sheet	2	of	3	Attorney Docket Number	27132
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	1	Abrahamson et al. "Glomerular Development in Intraocular and Intrarenal Grafts of Fetal Kidneys", Laboratory Investigation, 64(5): 629-639, 1991.			
	2	Barakat et al. "The Capacity of Fetal and Neonatal Renal Tissues to Regenerate and Differentiate in A Heterotopic Allogeneic Subcutaneous Tissue Site in the Rat", Journal of Anatomy, 110(3): 393-407, 1971.			
	3	Barry "Renal Transplantation", Current Opinion in Urology, 10(4): 121-127, 1999.			
	4	Björklund et al. "Embryonic Stem Cells Develop Into Functional Dopaminergic Neurons After Transplantation in A Parkinson Rat Model", Proc. Natl. Acad. Sci. USA (PNAS), 99(4): 2344-2349, 2002.			
	5	Brandhagen "Liver Transplantation for Hereditary Hemochromatosis", Liver Transplantation, 7(8): 663-672, 2001.			
	6	Cecka "Kidney Transplantation From Living Unrelated Donors", Annual Review of Medicine, 51:393-406, 2000.			
	7	Curtis "End-Stage Renal Disease Patients: Referral for Transplantation", Journal of the American Society of Nephrology, 9: S137-S140, 1998.			
	8	Freed "Will Embryonic Stem Cells Be A Useful Source of Dopamine Neurons for Transplant Into Patients With Parkinson's Disease? Proc. Natl. Acad. Sci. USA (PNAS), 99(4): 1755-1757, 2002.			
	9	French et al. "Progress in Renal Transplantation", The Canadian Journal of Urology, 7(3): 1030-1037, 2000.			
	10	Frilling et al. "Current Status of Liver Transplantation for Treatment of Hepatocellular Carcinoma", Digestive Diseases, 19: 333-337, 2001.			
	11	Hammerman "Transplantation of Embryonic Kidneys", Clinical Science, 103: 599-612, 2002.			
	12	Hammerman "Transplantation of Embryonic Organs - Kidney and Pancreas", American Journal of Transplantation, 4(Suppl.6): 14-24, 2004.			
	13	Ishizaka et al. "Development of Hepatocytes From ES Cells After Transfection With the HNF-3β Gene", The FASEB Journal, 16: 1444-1446, 2002.			
	14	Jones et al. "Hepatic Differentiation of Murine Embryonic Stem Cells", Experimental Cell Research, 272: 15-22, 2002.			
	15	Kanai et al. "Delayed Hyperacute Xenograft Rejection in Porcine to Canine Fetal Liver Transplantation", Transplant Immunology, 7: 95-99, 1999.			
	16	Keeffe "Liver Transplantation at the Millenium - Past, Present, and Future", Hepatology: A Century of Progress, P.242-255, 2000.			
	17	Keeffe "Liver Transplantation: Current Status and Novel Approaches to Liver Replacement", Gastroenterology, 120: 749-762, 2001.			
	18	Kokudo et al. "Allogeneic Hepatocyte and Fetal Liver Transplantation and Xenogeneic Hepatocyte Transplantation for Nagase's Albuminemic Rats", Cell Transplantation, 5(5S-1): S21-S22, 1996.			
	19	Reubinoff et al. "Embryonic Stem Cell Lines From Human Blastocysts: Somatic Differentiation In Vitro", Nature Biotechnology, 18: 399-404, 2000.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount



PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/759,033
				Filing Date	January 20, 2004
				First Named Inventor	Yair REISNER et al
				Group Art Unit	1651
				Examiner Name	LANKFORD JR, LEON B
Sheet	3	of	3	Attorney Docket Number	27132
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	20	Robert et al. "Evidence That Embryonic Kidney Cells Expressing Flk-1 Are Intrinsic, Vasculogenic Angioblasts", The American Journal of Physiology, 271 (Renal Fluid Electrolyte Physiology 40): F744-F753, 1996.			
	21	Rogers et al. "Transplantation of Pig Metanephroi", ASAIO Journal, 49: 48-52, 2003.			
	22	Seaman "Adult Living Donor Liver Transplantation: Current Status", Journal of Clinical Gastroenterology, 33(2): 97-106, 2001.			
	23	Takebe et al. "Xenogeneic (Pig to Rat) Fetal Liver Fragment Transplantation Using Macrocapsules for Immunoisolation", Cell Transplantation, 5(5S-1): S31-S33, 1996.			
	24	Thomson et al. "Embryonic Stem Cell Lines Derived From Human Balstocysts", Science, 282: 1145-1147, 1998.			
	25	Van Thiel et al. "Liver Transplantation for Fulminant Hepatic Failure", Journal of Gastroenterology, 36: 1-4, 2001.			
	26	Xie et al. "Expression, Roles, Receptors, and Regulation of Osteopontin in the Kidney", Kidney International, 60: 1645-1657, 2001.			
	27	Ramanathan et al. "Renal Transplantation", Seminars in Nephrology, 21(2): 213-219, 2001.			
Signature				Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Applicant's unique citation designation number (optional). ². Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.